巨子生物(2367.HK):首个III类医疗器械注册证获批 前景可期

华泰证券
18 Dec 2024

17 日公司公众号披露获得首个III 类医疗器械注册证,为骨修复材料。此外,另一款III 类医疗器械“注射用重组胶原蛋白填充剂”(用于颈纹)“列入国家重点研发计划的医疗器械”,近日列入优先审批通道,产品上市时间有望缩短;此外我们预计其用于眼部细纹填充的医美产品有望于25Q1 获批,或为公司医美领域III 类首证。此前市场对于公司医美领域III 类医疗器械的获批节奏存在担忧,近期公司在该领域的积极...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10